Veracyte, Inc. - stock earnings
VCYT Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -28.3 million USD | 98.2 million USD |
| 2023Q3 | -29.6 million USD | 90.1 million USD |
| 2023Q2 | -8.4 million USD | 90.3 million USD |
| 2023Q1 | -5.7 million USD | 82.4 million USD |
| 2022Q4 | -3.8 million USD | 80.3 million USD |
| 2022Q3 | -8.7 million USD | 75.6 million USD |
| 2022Q2 | -9.5 million USD | 72.9 million USD |
| 2022Q1 | -14.5 million USD | 67.8 million USD |
| 2021Q4 | -10.5 million USD | 67.3 million USD |
| 2021Q3 | -14.1 million USD | 60.4 million USD |
| 2021Q2 | -9.0 million USD | 55.1 million USD |
| 2021Q1 | -41.9 million USD | 36.7 million USD |
| 2020Q4 | -8.0 million USD | 34.5 million USD |
| 2020Q3 | -4.1 million USD | 31.1 million USD |
| 2020Q2 | -11.0 million USD | 20.7 million USD |
| 2020Q1 | -11.7 million USD | 31.1 million USD |
| 2019Q4 | -7.5 million USD | 29.7 million USD |
| 2019Q3 | -730000 USD | 31.0 million USD |
| 2019Q2 | -2.5 million USD | 30.1 million USD |
| 2019Q1 | -1.9 million USD | 29.5 million USD |
| 2018Q4 | -3.1 million USD | 25.8 million USD |
| 2018Q3 | -4.5 million USD | 23.5 million USD |
| 2018Q2 | -6.2 million USD | 22.8 million USD |
| 2018Q1 | -9.2 million USD | 20.0 million USD |
| 2017Q4 | -8.4 million USD | 19.6 million USD |
| 2017Q3 | -7.0 million USD | 17.5 million USD |
| 2017Q2 | -7.3 million USD | 18.4 million USD |
| 2017Q1 | -8.2 million USD | 16.4 million USD |
| 2016Q4 | -4.4 million USD | 18.3 million USD |
| 2016Q3 | -5.6 million USD | 18.6 million USD |
| 2016Q2 | -11.2 million USD | 14.7 million USD |
| 2016Q1 | -10.1 million USD | 13.6 million USD |
| 2015Q4 | -8.0 million USD | 14.0 million USD |
| 2015Q3 | -8.9 million USD | 12.3 million USD |
| 2015Q2 | -9.1 million USD | 11.9 million USD |
| 2015Q1 | -7.6 million USD | 11.2 million USD |
| 2014Q4 | -8.1 million USD | 12.2 million USD |
| 2014Q3 | -7.9 million USD | 9.8 million USD |
| 2014Q2 | -6.7 million USD | 8.7 million USD |
| 2014Q1 | -6.7 million USD | 7.5 million USD |
| 2013Q4 | -5.9 million USD | 6.8 million USD |
| 2013Q3 | -6.3 million USD | 5.6 million USD |
| 2013Q2 | -6.5 million USD | 5.1 million USD |
| 2013Q1 | -6.9 million USD | 4.4 million USD |
| 2012Q4 | -4.8 million USD | 4.5 million USD |
| 2012Q3 | -4.9 million USD | 3.2 million USD |
| 2012Q2 | ? USD | 2.5 million USD |
| 2012Q1 | ? USD | 1.5 million USD |
| 2011Q4 | ? USD | 2.6 million USD |
VCYT Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -74.4 million USD | 361.1 million USD |
| 2022 | -36.6 million USD | 296.5 million USD |
| 2021 | -75.6 million USD | 219.5 million USD |
| 2020 | -35.8 million USD | 117.5 million USD |
| 2019 | -16.5 million USD | 120.4 million USD |
| 2018 | -23.0 million USD | 92.0 million USD |
| 2017 | -31.0 million USD | 72.0 million USD |
| 2016 | -31.4 million USD | 65.1 million USD |
| 2015 | -33.7 million USD | 49.5 million USD |
| 2014 | -29.4 million USD | 38.2 million USD |
| 2013 | -25.6 million USD | 21.9 million USD |
| 2012 | -18.6 million USD | 11.6 million USD |
| 2011 | -14.4 million USD | 2.6 million USD |
VCYT
Price: $20.35
52 week price:
Payout Ratio Range:
Earnings Per Share: -1.02 USD
P/E Ratio: -35.43
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 321710
Ebitda: -5.2 millionMarket Capitalization: 1.5 billion